ESMO 2018 | Ovarian news from ESMO 2018: SOLO-1 results for olaparib

Name: Ovarian news from ESMO 2018: SOLO-1 results for olaparib
Uploaded: 2018-10-21T15:31:34.000Z
Duration: 7 min 39 s
Description: Ovarian cancer research is moving forwards, as displayed at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Kathleen Moore, MD, MS, of the Stephenson Cancer Center, Oklahoma City, OK, gave an update on the SOLO-1 trial (NCT01844986) of olaparib maintenance monotherapy for BRCA-mutated ovarian cancer after first-line platinum-based chemotherapy.

Kathleen Moore • 21 Oct 2018

ESMO 2018

Gynecological Cancer Ovarian Cancer Olaparib

SOLO-1

Ovarian cancer research is moving forwards, as displayed at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Kathleen Moore, MD, MS, of the Stephenson Cancer Center, Oklahoma City, OK, gave an update on the SOLO-1 trial (NCT01844986) of olaparib maintenance monotherapy for BRCA-mutated ovarian cancer after first-line platinum-based chemotherapy.